A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00820664
First received: January 8, 2009
Last updated: May 10, 2010
Last verified: May 2010

January 8, 2009
May 10, 2010
December 2008
May 2009   (final data collection date for primary outcome measure)
Immunohistochemistry (IHC) Proliferative Effects Measurement [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.
To examine the proliferative effects on the uterine endometrial tissue as measured by IHC after 4 weeks of either 0.5 or 2 mg Estrace compared to placebo. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00820664 on ClinicalTrials.gov Archive Site
Mean Gene Expression Intensity After 4 Weeks of Either 0.5 or 2 mg Estrace Compared to Placebo. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
A Randomized Clinical Trial to Evaluate the Effects of Estrogen on Uterine Endometrium in Healthy Postmenopausal Women

The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining (endometrium).

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Diagnostic
Postmenopausal Symptoms
  • Drug: Comparator: Estrace 0.5 mg
    0.5 mg tablet taken once daily for 28 days
    Other Name: Estrace
  • Drug: Comparator: Estrace 2 mg
    2 mg tablets taken once daily for 28 days.
    Other Name: Estrace
  • Drug: Comparator: Placebo
    Placebo 0 mg capsule taken once daily for 28 days
  • Active Comparator: 17β-estradiol 2.0 milligrams
    Estrace 2.0 mg tablet
    Intervention: Drug: Comparator: Estrace 2 mg
  • Active Comparator: 17β-estradiol 0.5 milligrams
    Estrace 0.5 mg tablet
    Intervention: Drug: Comparator: Estrace 0.5 mg
  • Placebo Comparator: 3
    Placebo
    Intervention: Drug: Comparator: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
June 2009
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is a healthy postmenopausal woman less than or equal to 65 years of age with onset of menopause less than or equal to 10 years prior to prestudy visit 1
  • Patient has a uterus and no history of uterine bleeding in the past 3 months
  • Patient has not had a previous endometrial biopsy within the last 4 weeks
  • Patient has had a normal mammogram within the last 11 months
  • Patient has had a normal pap-smear within the past 3 years prior to screening
  • Patient has had a normal transvaginal ultrasound of the endometrium
  • Patient is willing to avoid strenuous physical activity such as strenuous or unaccustomed weight lifting, running, bicycling, etc for the duration of the study
  • Patient agrees to not consume grapefruit products beginning approximately 2 weeks prior to the first dose of study drug and throughout the study
  • Patient agrees to limit daily consumption of alcohol. During the study, daily alcohol consumption should not be more than 2 glasses
  • Patient agrees to limit daily consumption of caffeine. During the study, daily caffeine consumption should not exceed 3 cups of coffee
  • Patient is a non-smoker

Exclusion Criteria:

  • Patient is mentally or legally incapacitated
  • Patient has a history of any first degree relatives with breast or endometrial cancer
  • Patient has a history of multiple and/or severe allergies to prescription or non-prescription drugs or food
  • Patient has used any type of estrogen or progesterone preparation unless followed by appropriate wash-out periods
  • Patient has had surgery, donated approximately 500 mL of blood or has participated in another investigational study within the last 4 weeks
  • Patient has a history of deep vein thromboses, coronary artery disease, heart attack or stroke
  • Patient is a current user of illegal drugs
  • Patient has a history of hypersensitivity to estrogen products
  • Patient is unable to refrain from using anti-coagulants
Female
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00820664
2009_505, 122
No
Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
Merck
Not Provided
Study Director: Medical Monitor Merck
Merck
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP